133 related articles for article (PubMed ID: 3421908)
1. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
2. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism.
Rodriguez E; Nan R; Li K; Gor J; Perkins SJ
J Biol Chem; 2015 Jan; 290(4):2334-50. PubMed ID: 25488663
[TBL] [Abstract][Full Text] [Related]
3. Zinc-induced self-association of complement C3b and Factor H: implications for inflammation and age-related macular degeneration.
Nan R; Tetchner S; Rodriguez E; Pao PJ; Gor J; Lengyel I; Perkins SJ
J Biol Chem; 2013 Jun; 288(26):19197-210. PubMed ID: 23661701
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of complement inhibition by the trypanosome receptor ISG65.
Cook AD; Carrington M; Higgins MK
Elife; 2024 Apr; 12():. PubMed ID: 38655765
[TBL] [Abstract][Full Text] [Related]
5. Complement activation in the arteries of patients with severe atherosclerosis.
Ge X; Xu C; Liu Y; Zhu K; Zeng H; Su J; Huang J; Ji Y; Tan Y; Hou Y
Int J Clin Exp Pathol; 2018; 11(1):1-9. PubMed ID: 31938082
[TBL] [Abstract][Full Text] [Related]
6. A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism.
Andersen JF; Lei H; Strayer EC; Kanai T; Pham V; Pan XZ; Alvarenga PH; Gerber GF; Asojo OA; Francischetti IMB; Brodsky RA; Valenzuela JG; Ribeiro JMC
Blood; 2023 Jun; 141(25):3109-3121. PubMed ID: 36947859
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of complement C3c, iC3b, and cells containing CD11b or CD14 in experimentally induced psoriatic lesion.
Rahkola D; Harvima RJ; Harvima IT
Clin Exp Immunol; 2024 May; 216(3):252-261. PubMed ID: 38310540
[TBL] [Abstract][Full Text] [Related]
8. A novel assay that characterizes properdin function shows neutrophil-derived properdin has a distinct oligomeric distribution.
Moore SR; Menon SS; Galwankar NS; Khuder SA; Pangburn MK; Ferreira VP
Front Immunol; 2022; 13():918856. PubMed ID: 36713423
[TBL] [Abstract][Full Text] [Related]
9. Structural studies offer a framework for understanding the role of properdin in the alternative pathway and beyond.
Pedersen DV; Lorentzen J; Andersen GR
Immunol Rev; 2023 Jan; 313(1):46-59. PubMed ID: 36097870
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the Complement System by Neoplastic Disease of the Central Nervous System.
Yarmoska SK; Alawieh AM; Tomlinson S; Hoang KB
Front Immunol; 2021; 12():689435. PubMed ID: 34671342
[TBL] [Abstract][Full Text] [Related]
11. The Brilliance of
Anderson C; Brissette CA
Pathogens; 2021 Mar; 10(3):. PubMed ID: 33801255
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Complement Properdin in Cancer.
Mangogna A; Varghese PM; Agostinis C; Alrokayan SH; Khan HA; Stover CM; Belmonte B; Martorana A; Ricci G; Bulla R; Kishore U
Front Immunol; 2020; 11():614980. PubMed ID: 33542722
[TBL] [Abstract][Full Text] [Related]
13. Properdin oligomers adopt rigid extended conformations supporting function.
Pedersen DV; Pedersen MN; Mazarakis SM; Wang Y; Lindorff-Larsen K; Arleth L; Andersen GR
Elife; 2021 Jan; 10():. PubMed ID: 33480354
[TBL] [Abstract][Full Text] [Related]
14. Quantification of Factor H Mediated Self vs. Non-self Discrimination by Mathematical Modeling.
Tille A; Lehnert T; Zipfel PF; Figge MT
Front Immunol; 2020; 11():1911. PubMed ID: 33013842
[TBL] [Abstract][Full Text] [Related]
15. Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b.
van den Bos RM; Pearce NM; Granneman J; Brondijk THC; Gros P
Front Immunol; 2019; 10():2097. PubMed ID: 31552043
[TBL] [Abstract][Full Text] [Related]
16. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.
Pedersen DV; Gadeberg TAF; Thomas C; Wang Y; Joram N; Jensen RK; Mazarakis SMM; Revel M; El Sissy C; Petersen SV; Lindorff-Larsen K; Thiel S; Laursen NS; Fremeaux-Bacchi V; Andersen GR
Front Immunol; 2019; 10():2007. PubMed ID: 31507604
[TBL] [Abstract][Full Text] [Related]
17. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?
Michels MAHM; Volokhina EB; van de Kar NCAJ; van den Heuvel LPWJ
Pediatr Nephrol; 2019 Aug; 34(8):1349-1367. PubMed ID: 30141176
[TBL] [Abstract][Full Text] [Related]
18. Properdin: A multifaceted molecule involved in inflammation and diseases.
Chen JY; Cortes C; Ferreira VP
Mol Immunol; 2018 Oct; 102():58-72. PubMed ID: 29954621
[TBL] [Abstract][Full Text] [Related]
19. The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?
Harrison RA
Semin Immunopathol; 2018 Jan; 40(1):15-35. PubMed ID: 29167939
[TBL] [Abstract][Full Text] [Related]
20. Functional and structural insight into properdin control of complement alternative pathway amplification.
Pedersen DV; Roumenina L; Jensen RK; Gadeberg TA; Marinozzi C; Picard C; Rybkine T; Thiel S; Sørensen UB; Stover C; Fremeaux-Bacchi V; Andersen GR
EMBO J; 2017 Apr; 36(8):1084-1099. PubMed ID: 28264884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
